• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Humacyte Inc. (Amendment)

    2/14/22 4:30:50 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HUMA alert in real time by email
    SC 13G/A 1 ahac20211231.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
     
     

    Humacyte, Inc. formerly known as Alpha Healthcare Acquisition Corp.

    (Name of Issuer)
     

    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    020751202

    (CUSIP Number)
     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    o Rule 13d-1(c)
    o Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    1

    NAME OF REPORTING PERSON

    Glazer Capital, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

    12

    TYPE OF REPORTING PERSON

    IA, OO

             

     

     
     

     

     

    1

    NAME OF REPORTING PERSON

    Paul J. Glazer

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     
     

     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Humacyte, Inc. formerly known as Alpha Healthcare Acquisition Corp. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 2525 East North Carolina, Highway 54, Durham, NC

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:
       
      (i) Glazer Capital, LLC, a Delaware limited liability company ("Glazer Capital"), with respect to the shares of Common Stock (as defined in Item 2(d)) held by certain funds and managed accounts to which Glazer Capital serves as investment manager (collectively, the "Glazer Funds"); and
       
      (ii) Mr. Paul J. Glazer ("Mr. Glazer"),  who serves as the Managing Member of Glazer Capital, with respect to the shares of Common Stock held by the Glazer Funds.
       
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 250 West 55th Street, Suite 30A, New York, New York 10019.

     

    Item 2(c). CITIZENSHIP:
       
      Glazer Capital is a Delaware limited liability company.  Mr. Glazer is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Class A Common Stock, par value $0.0001 per share

     

    Item 2(e). CUSIP NUMBER:
       
      020751202

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
     
     

     

      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ý Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) ý

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:

     

    Item 4. OWNERSHIP
       
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
       

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
     
     

     

       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of its or his knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

     

    SIGNATURES

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 14, 2022

     

    GLAZER CAPITAL, LLC    
         
         
    By: /s/ Paul J. Glazer    
    Name: Paul J. Glazer    
    Title: Managing Member    
         
         
    /s/ Paul J. Glazer    
    PAUL J. GLAZER    

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     
     

     

     

     

     

    EXHIBIT I

     

    JOINT FILING AGREEMENT

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

     

    DATED as of February 14, 2022

     

    GLAZER CAPITAL, LLC    
         
         
    By: /s/ Paul J. Glazer    
    Name: Paul J. Glazer    
    Title: Managing Member    
         
         
    /s/ Paul J. Glazer    
    PAUL J. GLAZER    

     

    Get the next $HUMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HUMA

    DatePrice TargetRatingAnalyst
    8/27/2025$3.50Overweight
    Barclays
    5/14/2025$4.00Buy
    H.C. Wainwright
    12/20/2024$12.00 → $15.00Buy
    H.C. Wainwright
    12/11/2023$6.00Buy
    H.C. Wainwright
    8/14/2023$2.75 → $3.50Underweight → Neutral
    Piper Sandler
    6/22/2023$6.00Overweight
    Cantor Fitzgerald
    5/16/2022$10.00 → $4.00Overweight → Underweight
    Piper Sandler
    10/29/2021$17.00Outperform
    Cowen & Co.
    More analyst ratings

    $HUMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

    DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the recently adopted FY 2026 U.S. Department of Defense (DoD) Appropriations Act includes dedicated funding to support the evaluation and incorporation of biologic vascular repair technologies for the warfighters suffering from traumatic vascular injuries. The FY2026 National Defense Authorization Act (NDAA), enacted in December 2025, stated in report language that DoD should "integrate FDA-approved breakthrough vascular repair technologies in traumatic extre

    2/9/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

    - Data is from comprehensive review of hospital charges and all-payer claims over five years -  - Preventable complications such as amputation and conduit infection increased initial hospital charges by approximately $493,000 and $590,000 per patient respectively – - Humacyte's Symvess® has consistently demonstrated low rates of infection and high rates of limb salvage – DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the results of a five-year retrospective analysis of hospital charges, payer costs, and hea

    1/8/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel

    - Expansion plans are based on requests for product access received from surgeons and hospitals in Israel -  - Expansion of Symvess into other territories, including those in Europe and the Middle East, is also planned - DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it plans to file a Marketing Authorization Application (MAA) with the Israel Ministry of Health for approval of the acellular tissue engineered vessel (ATEV™ or Symvess) for arterial trauma repair during the first quarter of 2026. The Compa

    1/5/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HUMA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Humacyte Inc.

    SCHEDULE 13D/A - Humacyte, Inc. (0001818382) (Subject)

    1/9/26 11:42:54 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humacyte Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Humacyte, Inc. (0001818382) (Filer)

    12/16/25 5:30:42 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Humacyte Inc.

    424B5 - Humacyte, Inc. (0001818382) (Filer)

    12/16/25 5:30:17 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HUMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Scheessele William John bought $9,999 worth of shares (6,493 units at $1.54), increasing direct ownership by 42% to 22,018 units (SEC Form 4)

    4 - Humacyte, Inc. (0001818382) (Issuer)

    4/15/25 4:03:35 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CFO and Chief Corp. Deve. Off. Sander Dale A. bought $30,600 worth of shares (20,000 units at $1.53) (SEC Form 4)

    4 - Humacyte, Inc. (0001818382) (Issuer)

    4/14/25 9:00:23 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Parikh Shamik J bought $11,625 worth of shares (7,500 units at $1.55) (SEC Form 4)

    4 - Humacyte, Inc. (0001818382) (Issuer)

    4/14/25 9:00:12 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HUMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $HUMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 4 filed by Former 10% Shareholder Fresenius Medical Care Holdings Inc /Ny/

    4 - Humacyte, Inc. (0001818382) (Issuer)

    12/8/25 2:20:30 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CFO and Chief Corp. Deve. Off. Sander Dale A. was granted 311,100 shares, increasing direct ownership by 15,555% to 313,100 units (SEC Form 4)

    4 - Humacyte, Inc. (0001818382) (Issuer)

    11/17/25 5:52:29 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Parikh Shamik J was granted 311,100 shares, increasing direct ownership by 4,148% to 318,600 units (SEC Form 4)

    4 - Humacyte, Inc. (0001818382) (Issuer)

    11/17/25 5:51:24 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays initiated coverage on Humacyte with a new price target

    Barclays initiated coverage of Humacyte with a rating of Overweight and set a new price target of $3.50

    8/27/25 8:22:05 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Humacyte with a new price target

    H.C. Wainwright resumed coverage of Humacyte with a rating of Buy and set a new price target of $4.00

    5/14/25 11:33:51 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright reiterated coverage on Humacyte with a new price target

    H.C. Wainwright reiterated coverage of Humacyte with a rating of Buy and set a new price target of $15.00 from $12.00 previously

    12/20/24 8:28:06 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HUMA
    Financials

    Live finance-specific insights

    View All

    Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

    - Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement -  - Major advances in pipeline as Humacyte moves closer to planned BLA filing in dialysis and first-in-human studies in cardiac bypass graft surgery – – IND submitted to the FDA for the CABG indication – - Symvess™ and pipeline programs highlighted in multiple scientific publications and presentations - - Conference call today at 8:00 am ET - DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercia

    11/12/25 7:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

    DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended September 30, 2025, on Wednesday, November 12, 2025. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. Title:Humacyte Third Quarter 2025 Financial Results and Corporate UpdateDate:November 12, 2025Time:8:00 AM Eastern TimeConference Call Details:1-877-704-4453 (U.S. Investors Dial)1-201-389-0920 (International Investors Dial)13756236 (Conference ID)Call me™ Feature

    11/6/25 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

    DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended June 30, 2025, on Monday, August 11, 2025. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. Title:Humacyte Second Quarter 2025 Financial Results and Corporate UpdateDate:August 11, 2025Time:8:00 AM Eastern TimeConference Call Details:1-877-704-4453 (U.S. Investors Dial)1-201-389-0920 (International Investors Dial)13754596 (Conference ID)Call meTM Feature: Click Here

    8/7/25 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HUMA
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Juliana Blum Joins BioAesthetics as CEO

    BioAesthetics Corporation announced today the appointment of Juliana Blum, PhD as its new Chief Executive Officer, effective August 12, 2024. Dr. Sandra Coufal, MD, Director of BioAesthetics and CEO of Toragen, Inc. said, "This is an important milestone for BioAesthetics. During the development of every successful biotech company, there comes a time when the founding CEO transitions to a different role and a new CEO with different skill sets is needed for product advancement and commercialization. Dr. Blum's experience with novel products as co-founder of Humacyte will help guide further progress at BioAesthetics." Dr. Blum joins BioAesthetics following her 20 years spent as Co-founder

    8/26/24 2:00:00 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humacyte Expands Board of Directors with Appointment of Diane Seimetz, Ph.D.

    DURHAM, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Diane Seimetz, Ph.D., to its board of directors. "Diane is an innovator and strategist with extensive experience in the biopharmaceutical industry, and we are delighted to welcome her to the Humacyte board," said Kathleen Sebelius, Chair of Humacyte's board of directors. "Her expertise in guiding companies with innovative products to the market will be invaluable as Humacyte moves toward commercialization of the Human Acellular VesselTM (HAV). We al

    6/27/22 7:30:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humacyte Expands Leadership Team with Appointment of Shamik Parikh, M.D., as Chief Medical Officer

    --Seasoned physician, scientist and life science executive brings expertise in clinical research and development across product life cycle-- --Key appointment as Humacyte advances HAV through multiple late-stage clinical trials in initial vascular applications-- DURHAM, N.C., April 05, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Shamik J. Parikh, M.D., as Chief Medical Officer. In this role, Dr. Parikh will lead the company's global clinical development strategy, including oversight of the preclinical and clinical

    4/5/22 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HUMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    11/20/24 7:10:08 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    11/18/24 4:10:14 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    9/3/24 4:11:41 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care